BRAND NAMES
 MECHANISM OF ACTION
Both cinnarizine and dimenhydrinate are known to be effective in the treatment of vertigo. The combination product is more effective than the individual compounds:
- Dimenhydrinate, an anti-nauseant/antimemetic is the 8-Chlorotheophylline salt of diphenhydramine. 8-Chlorotheophylline, a mild central nervous system stimulants was added in order to counteract drowsiness.
Dimenhydrinate acts as antihistamine (H1-antagonist) with anticholinergic (antimuscarinic), exerting parasympatholytic and centrally-depressant effects. its antiemetic and antivertiginous effects may be related to the central anticholinergic actions on the central vestibular system: Dimenhydrinate diminish vestibular stimulation and depress labyrinthine function.
- Cinnarizine is an histamine H1 antagonist, a calcium channel blocker that inhibits contractions of vascular smooth muscle cells by blocking T-type voltage gated calcium channels and a muscarinic acetycholine receptors antagonist.
Cinnarizine reduces the vestibular sensitivity, preventing acute episodes of vertigo.
- Treatment of vertigo symptoms of various origins
- Adults and Elderly: 1 tablet (20 mg cinnarizine/40 mg dimenhydrinate) three times daily, to be taken unchewed with some liquid after meals to minimise any gastric irritation.
- Hypersensitivity to Dimenhydrinate or Cinnarizine
- Severe hepatic impairment
- Severe renal impairment
- Patients with angle-closure glaucoma
- Urine retention due to an enlargement of the prostate gland
- Patients with convulsions
 WARNINGS AND PRECAUTIONS
- May reduce blood pressure: Use with caution in hypotensive patients.
- Use with caution in patients with conditions that might be aggravated by anticholinergic therapy, e.g. raised intra-ocular pressure, pyloro-duodenal obstruction, prostatic hypertrophy, hypertension, hyperthyroidism or severe coronary heart disease.
- Avoid alcoholic beverages.
- May cause drowsiness, especially at the start of treatment. Patients affected in this way should not drive or operate machinery.
- The effects of hypnotic, sedative and tranquilizing drugs may be synergistic if given concomitantly.
- Concomitant administration of medicines that prolong the QT interval of the ECG (such as Class Ia and Class III antiarrhythmics: disopyramide, amiodarone, sotalol) should be avoided
 PREGNANCY AND LACTATION
- Should not be used during pregnancy
- Dimenhydrinate and cinnarizine are excreted in human breast milk. the drug should not be taken by women who are breast feeding.
 SIDE EFFECTS
The most frequently occurring are somnolence (including drowsiness, tiredness, fatigue, daze) and dry mouth. These reactions are usually mild and disappear within a few days even if treatment is continued.
 RELATED LINKS
|Betahistine • Cinnarizine • Dimenhydrinate/Cinnarizine • Flunarizine • Piracetam • Prochlorperazine|
|5-HT3 receptor antagonists||Dolasetron • Granisetron • Ondansetron • Palonosetron • Tropisetron|
|Dopamine antagonists||Alizapride • Bromopride • Clebopride • Domperidone • Metoclopramide • Prochlorperazine • Thiethylperazine|
|H1 antagonists||Dimenhydrinate • Meclizine|
|NK1 receptor antagonists||Aprepitant • Fosaprepitant • Maropitant|
|Motion sickness||Cinnarizine • Dimenhydrinate • Meclizine • Meclizine/Pyridoxine • Scopolamine (Patch)|
|Pregnancy||Meclizine/Pyridoxine • Ondansetron|